From The Editor
-
Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals
3/22/2024
AstraZeneca's $2.4 billion acquisition of Fusion Pharma is the third billion dollar radiopharmaceuticals deal in recent months. John Valliant, Fusion's founder and CEO, explains why alpha-emitters are better than beta-emitters, and why radiopharmaceuticals are poised for substantial growth.
-
A Proactive Approach To ‘Unscrupulous’ Patent Practices
3/7/2024
Terran Biosciences aims to subvert a patent strategy some drugmakers have used to delay the entrance of generic competitors. The company is patenting its own psychedelic salts, polymorphs, and prodrugs, and targeting FDA's 505(b)(2) pathway.
-
The Good And Bad Of Copromotion
2/26/2024
Are two minds, or companies, better than one for drug commercialization? It depends on the details, says Eisai's Paul Hawthorne.
-
Innovation From Animals And Evolution
2/1/2024
Insights gleaned from a variety of animal species, and a deeper understanding of evolution aided by artificial intelligence, could help bring a new wave of therapies to market.
-
Pharmaceutical Scientists’ Salaries in 2023
1/15/2024
The 2023 AAPS survey of pharmaceutical scientists' salaries showed a 6.7% jump over 2022, but the industry has work to do on closing the gender gap.
-
A New Year At Life Science Leader
1/1/2024
Life Science Leader wishes you a happy New Year and announces plans for 2024.
-
Leadership For Tomorrow
12/1/2023
Biopharma heavy hitters convened at the Galien Forum in New York City, offering tips and guidance for the leaders of tomorrow.
-
Krystal Biotech’s Side Business: Gene-Based Aesthetics
11/1/2023
Krystal Biotech's side business is an aesthetics company, Jeune Aesthetics, that uses the same platform and viral vector as Krystal to deliver collagen genes to consumers seeking aesthetic improvement.
-
A Family Affair
11/1/2023
For Krish and Suma Krishnan, the husband-and-wife leadership team at Krystal Biotech, bringing work home, and bringing home to work, is inevitable. A larger shared goal smooths the edges.
-
Too Much Talk About Technology
10/2/2023
To adopt and use new technology effectively, leaders should focus on people and their problems, not the technology itself, according to former Google executive turned biotech CEO.